Do you want to read an article? Please log in or register.
Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study
Genitourinary Cancer
Related content
Genitourinary Cancer
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532)
Ann Oncol.
Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, Carbone GM, Cavalli A, Pagano F, Ragazzi E, Prayer-Galetti T, Alimonti A
doi: 10.1016/j.annonc.2020.04.479.
Gastrointestinal Cancer
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network
Eur J Cancer
Bianchi S, Mosca A, Dalla Volta A, Prati V, Ortega C, Buttigliero C, Fea E, Vanella P, Valcamonico F, Zamparini M, Sirotova Z, Chiappino I, Dal Canton O, Masini C, Sacco C, Amoroso D, Montagnani F, Comandone A, Bellissimo AR, Ciccone G, Baier S, Gennari A, Tucci M, Berruti A
doi: 10.1016/j.ejca.2021.06.034
Gastrointestinal Cancer
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network
Eur J Cancer
Bianchi S, Mosca A, Dalla Volta A, Prati V, Ortega C, Buttigliero C, Fea E, Vanella P, Valcamonico F, Zamparini M, Sirotova Z, Chiappino I, Dal Canton O, Masini C, Sacco C, Amoroso D, Montagnani F, Comandone A, Bellissimo AR, Ciccone G, Baier S, Gennari A, Tucci M, Berruti A
doi: 10.1016/j.ejca.2021.06.034
Genitourinary Cancer
Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer
doi: 10.1016/j.eururo.2018.11.022.
Genitourinary Cancer
Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy
Eur Urol.
Sooriakumaran P, Nyberg T, Akre O, Widmark A, Hamdy F, Graefen M, Carlsson S, Steineck G, Wiklund NP
doi: 10.1016/j.eururo.2017.04.002.
Genitourinary Cancer
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur J Cancer
Nabid A, Carrier N, Vigneault E, Van Nguyen T, Vavassis P, Brassard MA, Bahoric B, Archambault R, Vincent F, Bettahar R, Wilke D, Souhami L
doi: 10.1016/j.ejca.2020.10.023
Genitourinary Cancer
Prostate Cancer Highlights from ASCO GU 2021: Cutting-Edge Results
healthbook TIMES Oncology Hematology
Alexander Meisel
doi: DOI: 10.36000/hbT.OH.2021.08.041
RECOMMENDED
Genitourinary CancerRadio-Oncology
Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer
Strahlenther Onkol.
Beck M, Böhmer D, Aebersold DM, Albrecht C, Flentje M, Ganswindt U, Höcht S, Hölscher T, Müller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Zschaeck S, Budach V, Wiegel T, Ghadjar P, Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO).
doi: 10.1007/s00066-019-01553-3.
RECOMMENDED
Genitourinary Cancer
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial
JAMA Oncol.
Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard AC, Delva R, Rolland F, Mouret L, Priou F, Beuzeboc P, Gravis G, Linassier C, Gomez P, Voog E, Muracciole X, Abraham C, Banu E, Ferrero JM, Ravaud A, Krakowski I, Lagrange JL, Deplanque G, Zylberait D, Bozec L, Houede N, Culine S, Elaidi
doi: 10.1001/jamaoncol.2018.6607.